Meeting Impression | Contemporary management of a patient with heart failure and diabetes: Implications from recent trialsMay 28, 2018 – Vienna, Austria
See below to download the Meeting Impression
This lunch symposium held during Heart Failure 2018 in Vienna, Austria, explored the role of diabetes treatment in the management of heart failure (HF), in light of recent findings that novel glucose-lowering drugs affect CV outcomes. Different classes of novel diabetes drugs were considered, along with their effects on HF in safety and outcome trials. Potential mechanisms underlying the observed effects are discussed, as well as how these drugs may be benefitted from in the management of patients with diabetes and HF.
This is a summary of the PACE symposium entitled '
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials', held during Heart Failure 2018 in Vienna, Austria.
During this Satellite Symposium, the role of diabetes treatment in the management of heart failure and novel interventions targeted to improve cardiovascular outcomes were discussed, addressing the following topics:
- Mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- The role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- An expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
- Current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events
Prof. Martin Cowie, MD – Imperial College London, United Kingdom: Current management of heart failure & T2DM
Prof. Naveed Sattar, MD – University of Glasgow, United Kingdom: Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes
Prof. Faiez Zannad, MD – CHU- Nancy University, France: Guidance from outcome trials: What are the clinical implications
The symposium was supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.